What is the recommended evaluation and treatment approach for a patient with renal cell carcinoma?

Renal Cell Carcinoma Evaluation and Treatment

Initial Diagnostic Work-Up

Obtain contrast-enhanced CT of chest, abdomen, and pelvis as the mandatory staging study for all suspected RCC patients. 1

Imaging Protocol

• Contrast-enhanced CT provides assessment of local invasiveness, lymph node involvement, and distant metastases 2
• For patients with CT contrast allergy or renal insufficiency, use high-resolution non-contrast chest CT plus abdominal MRI 1
• MRI provides additional information for assessing local advancement and venous tumor thrombus involvement 1
• Do not routinely perform bone scan or brain imaging unless clinical signs or symptoms are present 1
• FDG-PET is not standard and should not be used for diagnosis or staging of clear cell RCC 1

Tissue Diagnosis

• Obtain renal biopsy before ablative therapies and before starting systemic treatment in metastatic disease 1
• Biopsy provides high diagnostic accuracy with rare complications (bleeding is uncommon, tumor seeding is exceptional) 1
• Biopsy confirms malignancy, determines histologic subtype (clear cell, papillary type 1 or 2, chromophobe, collecting duct, medullary, or unclassified), and guides treatment selection 2, 1

Laboratory Assessment

• Obtain serum creatinine, hemoglobin, lactate dehydrogenase (LDH), C-reactive protein (CRP), and corrected calcium 1
• These tests are both prognostic and required for risk stratification 1
• Additional prognostic markers include leukocyte and platelet counts, and lymphocyte to neutrophil ratio 1

Staging and Risk Stratification

• Use UICC TNM 8 staging system 1
• Apply MSKCC risk classification for metastatic disease: five variables predict survival (Karnofsky performance status <70, elevated LDH, low hemoglobin, elevated corrected calcium, time from diagnosis to treatment <1 year) 2
• Patients stratify into favorable (no risk factors, median survival 30 months), intermediate (1-2 risk factors, median survival 14 months), or poor (≥3 risk factors, median survival 6 months) 2
• Fuhrman grading system (four-tiered based on nuclear morphology) is a significant prognostic factor in clear cell RCC 2

---

Treatment Algorithm by Stage

Localized Disease (T1-T2)

For organ-confined T1 tumors, partial nephrectomy is the preferred first-line treatment, preserving renal function with equivalent oncological outcomes to radical nephrectomy. 1

• For T1a tumors (≤4 cm), partial nephrectomy achieves 5-year cancer-specific survival >94% 3
• Laparoscopic radical nephrectomy is the preferred option for T2 tumors 1
• For patients medically unfit for surgery with biopsy-proven localized RCC (cT1a-T1b), SBRT achieves excellent local control rates of 94-100% with minimal toxicity 4
• Thermal ablation (radiofrequency ablation or cryoablation) can be considered for small cortical tumors ≤3 cm in high-risk surgical patients 4, 5
• Adjuvant therapy is not routinely recommended after nephrectomy - sunitinib showed disease-free survival benefit but no overall survival benefit and is not EMA-approved for adjuvant use 1

Locally Advanced Disease (T3-T4)

• Open radical nephrectomy is recommended for locally advanced RCC, though laparoscopic approach can be considered 1
• For unresectable local or recurrent disease where surgery cannot be performed, SBRT is an alternative 4

---

Treatment of Advanced/Metastatic Disease

First-Line Systemic Therapy

For intermediate and poor-risk advanced RCC patients, nivolumab plus ipilimumab is the recommended first-line treatment. 1, 6

• Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg IV every 2 weeks 6
• In the CHECKMATE-214 trial, this combination achieved 41.6% overall response rate (9.4% complete response) versus 26.5% with sunitinib in intermediate/poor-risk patients 6
• Median overall survival was not reached versus 25.9 months with sunitinib (HR 0.63, p<0.0001) 6
• Note: The efficacy of nivolumab plus ipilimumab in favorable-risk disease has not been established 6

Alternative First-Line Options for Clear Cell Carcinoma

• Nivolumab plus cabozantinib is approved for first-line treatment of advanced RCC 6
• Sunitinib or bevacizumab plus interferon are therapeutic options for good and intermediate risk patients 2
• Temsirolimus should be proposed to patients with poor risk features according to MSKCC classification 2

Role of Cytoreductive Nephrectomy

• Cytoreductive nephrectomy should be considered in patients with good performance status, except in intermediate- and poor-risk patients with asymptomatic primary tumors when medical treatment is required 1
• Cytoreductive nephrectomy appears to benefit many patients with metastatic RCC but should not be performed indiscriminately 2
• Metastasectomy may be an option, particularly in patients presenting with solitary metastasis 2

Second-Line Systemic Therapy

• Nivolumab or cabozantinib are recommended second-line options following TKI therapy 1
• For patients who have failed cytokines, sorafenib is recommended, with sunitinib remaining an option 2
• Everolimus has been shown to be active in patients who failed tyrosine kinase inhibitor 2

Non-Clear Cell Carcinoma

• There are very few data on efficacy of therapy in non-clear cell histology 2
• Sunitinib and sorafenib are considered possible options despite limited efficacy 2
• Temsirolimus might be an alternative based on subset analyses from pivotal phase III study 2

---

Radiation Therapy for Metastatic Disease

Palliative Radiation

• Radiation therapy is effective for palliation of symptomatic metastatic disease and prevention of progression in critical sites such as bone or brain 1, 4
• Local radiotherapy provides symptom relief in up to two-thirds of cases with complete responses in 20-25% for bone metastases 4
• For symptomatic bone metastases, use single fraction or fractionated radiotherapy 4
• For spinal cord compression in ambulatory patients with limited metastatic disease, surgery combined with radiotherapy improves survival and maintenance of ambulation compared with irradiation alone 4

Brain Metastases

• Whole-brain radiotherapy (WBRT) 20-30 Gy in 4-10 fractions is recommended for effective symptom control 1, 4
• For good-prognosis patients with a single unresectable brain metastasis, stereotactic radiosurgery (SRS) with or without WBRT should be considered, as SRS alone results in less late cognitive dysfunction 4

Oligometastatic Disease

• There is an emerging role for SBRT in synchronous or metachronous oligometastatic disease, oligoprogression, or mixed response scenarios with immuno- or targeted therapies 4
• Complete metastasectomy or local ablative therapy has been associated with improved overall survival in selected patients 4

---

Follow-Up Protocol

High-Risk Patients

• CT scans of thorax and abdomen every 3-6 months for the first 2 years after curative treatment 1, 5
• Continue surveillance beyond 2 years with gradually increasing intervals 1

Low-Risk Patients

• Annual CT scan after curative treatment 1

Metastatic Disease on Systemic Therapy

• 2-4 month follow-up intervals with CT scan during systemic therapy 1

---

Critical Pitfalls to Avoid

• Do not use radiotherapy in the neoadjuvant or adjuvant setting for primary RCC - four negative randomized trials demonstrate no benefit 4
• Do not delay surgical evaluation in operable candidates, as surgery remains first-line for resectable disease 4
• Do not attempt to downsize tumor thrombi or locally recurrent disease with systemic targeted therapy before surgery 5
• Ensure biopsy confirmation before SBRT or ablation to verify malignancy and histologic subtype 4, 5
• Do not perform routine extensive lymph node dissection unless there is clinical evidence of lymph node involvement 5